Speaker Profile

BM, BCh, Chief Scientific Officer, ArsenalBio

Biography
Nicholas Haining is a physician-scientist, immunologist and drug developer. He received his undergraduate and medical degree from Oxford University, UK. He completed his medical training in Pediatrics at Boston Childrens Hospital and in Pediatric Hematology/Oncology at Dana-Farber Cancer Institute. As an Associate Professor of Pediatrics at Harvard Medical School and an Associate Member of the Broad Institute of MIT and Harvard, his lab defined some of the key transcriptional and epigenetic regulators of T cell exhaustion and used in vivo genetic screens to identify immune vulnerabilities of cancer cells in mouse models. His clinical expertise is in hematopoietic stem cell transplantation and he attended on the bone marrow transplant service at Boston Children’s Hospital for almost twenty years. More recently, he served as Vice-President, Discovery Oncology and Immunology at Merck Research Laboratories, where he led a multi-site, multidisciplinary team developing innovative approaches to identify therapies for cancer and immune diseases.


 Session Abstract – PMWC 2023 Silicon Valley

Track 1 - January 26 9.00 A.M.-4.30 P.M.


Track Chair: Sharon Benzeno, Adaptive Biotechnologies

  • PMWC 2023 Luminary Award Ceremony
    Honoree: Bruce Levine, University of Pennsylvania
  • Advance and Optimize Cell Therapies in Oncology (PANEL)
    Chair: Sharon Benzeno, Adaptive Biotechnologies
    - Ira Mellman, Genenetch
    - Mark Selby, Walking Fish Therapeutics
    - Sneha Ramakrishna, Stanford
    - Loïc VINCENT, Affini-T Therapeutics
    - Nick Haining, Arsenal
    - Warner Biddle, Kite
  • Pioneering Cell Therapies in the Treatment of Autoimmune Disorders (PANEL)
    Chair: Carl June, UPenn
    - Lenny Dragone, Sonoma
    - James Chung, Kyverna
    - David Chang, Cabaletta
    - Cristina Musselli, Abata Therapeutics
  • Innovations in Cell Therapy Manufacturing (PANEL)
    Chair: Bruce Levine, University of Pennsylvania
    - Chris Holt, BMS
    - Heidi Hagen, Sonoma Bio
    - Rahul Singhvi, Resilience
    - Snehal Patel, Sana Biotechnology
  • Patentability of Immunotherapies - Latest Developments
    - Janet Xiao, Morrison & Foerster LLP
  • Investing in Gene-Modified Cell Therapies
    Chair: Karen Tkach Tuzman, BioCentury Inc.
    - Robert Lin, UPMC
    - Yvonne Yamanaka, venBio
    - Abraham Bassan, Samsara Capital
    - Brian Daniels, 5am Ventures
  • Leveraging Data Sets to Inform Future Drug Discovery and Development (PANEL)
    Chair: Jason Coloma, Maze Therapeutics
    - Peter DiLaura, Sonoma Bio
    - Nick Haining, Arsenal
    - Kwame Okrah, Parker Institute
    - Dan Kirouac, Notch Therapeutics